ALM has a much lower mutational burden than non-ALM cutaneous melanomas, including a lower incidence of activating mutations in BRAF and NRAS, variable KIT mutations, and a lack of ultraviolet (UV)-related mutational signatures (3, 7–9). The gene discussed is NRAS; the disease is acral lentiginous melanoma.